REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01252953|
Recruitment Status : Active, not recruiting
First Posted : December 3, 2010
Last Update Posted : March 21, 2017
|Condition or disease||Intervention/treatment||Phase|
|Atherosclerotic Cardiovascular Disease||Drug: anacetrapib Drug: placebo anacetrapib||Phase 3|
Sub-study: Does anacetrapib as a CETP inhibitor lead to mobilization of stem cells and enhance myocardial function via neoangiogenesis and tissue regeneration?
Following the main on-treatment part of the study, there will be a further period of at least 2 years during which participants will be followed-up by telephone, off treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30624 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||January 31, 2017|
|Estimated Study Completion Date :||April 2019|
tablet, 100mg daily
|Placebo Comparator: placebo anacetrapib||
Drug: placebo anacetrapib
tablet, 1 tablet daily
- Major coronary events (defined as coronary death, myocardial infarction or coronary revascularization procedure) [ Time Frame: Median follow-up of 4 years ]Primary assessment will involve an intention-to-treat comparison among all randomized participants of the effects of allocation to anacetrapib versus placebo on major coronary events (defined as the occurrence of coronary death, myocardial infarction or coronary revascularization procedure) during the scheduled treatment period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01252953
|CTSU, University of Oxford|
|Oxford, Oxfordshire, United Kingdom, OX3 7LF|
|Principal Investigator:||Martin Landray||University of Oxford|
|Principal Investigator:||Louise Bowman||University of Oxford|